Experts and Doctors on immunosuppressive agents in San Francisco, California, United States


Locale: San Francisco, California, United States
Topic: immunosuppressive agents

Top Publications

  1. Nakamura J, Garcia E, Pieper R. S6K1 plays a key role in glial transformation. Cancer Res. 2008;68:6516-23 pubmed publisher
    ..These findings implicate the mTOR-S6K pathway as a critical mediator of glial cell transformation. ..
  2. Harradine K, Ridd K, Saunier E, Clermont F, Perez Losada J, Moore D, et al. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res. 2009;15:5101-7 pubmed publisher
    ..Disparate P-Smad1/5/8 expression levels between keratoacanthoma from the two patient groups might reflect the distinct BMP-responsive cell of origin for this hair follicle-derived lesion. ..
  3. Penaranda C, Tang Q, Ruddle N, Bluestone J. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes. 2010;59:1461-8 pubmed publisher
    ..Our data show that TLOs are established during diabetes development and suggest that islet destruction is due to a loss of TLO integrity, which may be prevented by FTY720 treatment. ..
  4. Singer J, Huang M, Hui C, Blanc P, Boettger R, Golden J, et al. Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients. J Heart Lung Transplant. 2010;29:1009-13 pubmed publisher
    ..53). Standard dosing of enoxaparin in lung transplant recipients is associated with a high incidence of supratherapeutic anti-Xa levels. Further study will be required to correlate this finding with risk of hemorrhage. ..
  5. Walters T, Kim M, Denson L, Griffiths A, Dubinsky M, Markowitz J, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-? vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014;146:383-91 pubmed publisher
    ..Further data will be required to best identify children most likely to benefit from early treatment with anti-TNF? therapy. ..
  6. Lipshutz G, Flechner S, Govani M, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant. 2004;4:2132-4 pubmed
    ..These cases demonstrate that, unlike reports linking tacrolimus and PVAN, polyomavirus infection may develop in patients maintained on CNI-free immunosuppressive regimens and have not had episodes of rejection. ..
  7. Vagefi M, Kim E, Alvarado R, Duncan J, Howes E, Crawford J. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J Ophthalmol. 2005;139:370-3 pubmed
    ..S. prolificans is an opportunistic infection resistant to standard antifungal therapy that can result in endogenous endophthalmitis in immunocompromised individuals. ..
  8. Carter J, Melcher M, Carlson L, Roland M, Stock P. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753-60 pubmed
  9. Inductivo Yu I, Adams A, Gish R, Wakil A, Bzowej N, Frederick R, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799-802 pubmed
    ..MMF should be studied prospectively as an alternative agent in the treatment of autoimmune liver disease. ..

More Information


  1. Arnon T, Horton R, Grigorova I, Cyster J. Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress. Nature. 2013;493:684-8 pubmed publisher
    ..The results also show how adhesive differences of similar cells critically influence their behaviour in the same microenvironment...
  2. Pereira J, Xu Y, Cyster J. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS ONE. 2010;5:e9277 pubmed publisher
    ..We conclude that the S1P1-S1P pathway contributes to egress of immature-B cells from BM, and that this mechanism is partially redundant with other undefined pathways. ..
  3. Oza V, Mamlouk M, Hess C, Mathes E, Frieden I. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma. Pediatr Dermatol. 2016;33:e88-92 pubmed publisher
    ..Our report emphasizes the role for rapamycin in the treatment of KHE in the absence of KMP through the inhibition of vasculogenesis and fibrotic pathways. ..
  4. Vigne J, Hornung D, Mueller M, Taylor R. Purification and characterization of an immunomodulatory endometrial protein, glycodelin. J Biol Chem. 2001;276:17101-5 pubmed
    ..Our findings support the hypothesis that glycodelin reduces the local maternal inflammatory response toward the implantation of a semiallogeneic conceptus. ..
  5. Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Transplant. 2012;17:640-7 pubmed publisher
    ..Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function. ..
  6. Wang W, Graeler M, Goetzl E. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J. 2005;19:1731-3 pubmed
    ..1 T cells. Thus, S1P4 mediates immunosuppressive effects of S1P by inhibiting proliferation and secretion of effector cytokines, while enhancing secretion of the suppressive cytokine IL-10. ..
  7. Vogt A, Hebert J, Hwang J, Lu Y, Epstein E. Anti-rejection drug treatment increases basal cell carcinoma burden in Ptch1+/- mice. J Invest Dermatol. 2005;124:263-7 pubmed
    ..5-fold. Thus, these mice provide a good model for study of the effects of long-term administration of ARD on at least one type of non-melanoma skin cancer. ..
  8. Haskell C, Hancock W, Salant D, Gao W, Csizmadia V, Peters W, et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 2001;108:679-88 pubmed
    ..We conclude that Fk plays an important role in graft rejection. The development of CX(3)CR1 antagonists may allow reductions in the doses of immunosuppressive drugs used in transplantation. ..
  9. Gish R, Mason A. Autoimmune liver disease. Current standards, future directions. Clin Liver Dis. 2001;5:287-314 pubmed
    ..New immune tests may allow therapies to be customized to patients, and antiviral therapies may also eventually be used in the management of this autoimmune liver diseases. ..